Product Development Portfolio

Inflammation

  • Ulcerative Colitis Anti-inflammatory
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464 entering a Phase 2b clinical trial

    Description/Summary:

    ABX464 is an oral, first-in-class small molecule that has demonstrated anti-inflammatory activity in preclinical trials and shown impressive clinical safety and efficacy results in a Phase 2a proof of concept study in patients with ulcerative colitis.

    Read More

    Milestones:

    • Phase 2a data reported in H2 2018
    • Initiation of Phase 2b trial in H1 2019
  • Crohn’s Disease Anti-inflammatory
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464
  • Rheumatoid Arthritis Anti-inflammatory
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464

Antiviral

  • HIV Lasting viral remission
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464 Completed three Phase 2a clinical trials

    Description/Summary:

    ABX464 is an oral, first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long-lasting virological suppression in HIV-patients.

    Read More

    Milestones:

    • Phase 2a data delivered in H1 2018
    • Initiation of Phase 2b trials in H1 2019
  • Ebola Polyclonal antibodies
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX544
  • Respiratory Syncytial Virus Antiviral drug
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
  • Dengue Antiviral drug
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
  • Influenza Antiviral drug
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3

Cancer

  • Hepatocellular Cancer Immune Enhancer
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX196 in Phase 1/2 POC clinical trial in HCC to start H1 2019

    Description/Summary:

    ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.

    Read More

    Milestones:

    • Initiation of a Phase 1/2 trial in H1 2019